The FDA’s Whoop closeout sets a precedent: biometric features that stop short of clinical classification can qualify for exemption under the agency’s updated General Wellness policy. For wearable makers with advanced health metrics, the test is now intent and interface, not the measurement itself.
The American Food and Drug Administration (FDA) has closed its enforcement action against Whoop over the company’s Blood Pressure Insights feature, withdrawing a warning letter that had been active for nearly a year. The dispute became a test of where wellness ends and medicine begins for wearables, and the outcome matters beyond a single company’s regulatory file.
A warning, a policy shift, a resolution
In July 2025, the FDA sent Whoop a warning letter asserting that its Blood Pressure Insights (BPI) feature, which uses heart rate and blood flow patterns captured during sleep to generate daily estimates of systolic and diastolic blood pressure, constituted a medical device under federal law. The agency’s position was that blood pressure measurement is inherently diagnostic, tied to the detection of hypertension and hypotension, and therefore requires either premarket approval or 510(k) clearance before it can be marketed. (For readers outside the US: 510(k) clearance is the FDA’s “allowed to market” decision for many medical devices in the US.)
Whoop had neither.
Whoop founder and CEO Will Ahmed publicly rejected that thesis, arguing the feature fell under the 21st Century Cures Act, which exempts general wellness software from medical device classification when it is not intended to diagnose or treat disease.
The case ended through two parallel moves: Whoop modified its product and labeling, and the FDA updated its own guidance.
In January 2026, the FDA released an updated version of its General Wellness: Policy for Low Risk Devices guidance, concluding that blood pressure measurements do not automatically trigger medical device requirements when used for wellness purposes. On June 17, 2026, the agency formalized that position with a closeout letter to Whoop Inc., stating it does not intend to enforce device requirements against the modified version of BPI. The letter is explicit that the resolution is specific to this product and version: it applies to BPI as modified and does not extend to other Whoop features or future changes.
Commercial implications for Whoop and the sector
The resolution lifts an enforcement cloud that had hung over Whoop since mid 2025 and allows it to keep a feature central to its subscription positioning.
For the broader connected fitness and wearable sector, the Whoop case now offers a clearer route: features intended solely for wellness use, framed without diagnostic claims, and designed to avoid clinical signaling in the interface may qualify for exemption under the US General Wellness policy. That is a more workable path than seeking medical device clearance for every advanced biometric a platform might introduce.
